SEPN
Septerna, Inc. Common StockSEPN
SEPN
About: Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
Employees: 75
0
Funds holding %
of 7,429 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
317% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 6
78% more capital invested
Capital invested by funds: $262M [Q1] → $468M (+$206M) [Q2]
58% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 19
24% more funds holding
Funds holding: 71 [Q1] → 88 (+17) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]
2.57% less ownership
Funds ownership: 101.91% [Q1] → 99.34% (-2.57%) [Q2]
98% less call options, than puts
Call options by funds: $148K | Put options by funds: $7M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$26
117%
upside
Avg. target
$26
117%
upside
High target
$26
117%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Raghuram Selvaraju | 117%upside $26 | Buy Reiterated | 21 Aug 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
4 days ago
Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases
SOUTH SAN FRANCISCO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the dosing of the first participants in its Phase 1 clinical trial of SEP-631, a selective oral small molecule Mas-related G protein-coupled receptor X2 (MRGPRX2) negative allosteric modulator (NAM) being developed for the treatment of chronic spontaneous urticaria (CSU) and other mast cell-driven diseases.
Neutral
GlobeNewsWire
2 weeks ago
Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results
Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway Expected to Support Operating Plans at Least into 2029 SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted key business updates and upcoming milestones and reported financial results for the second quarter ended June 30, 2025.
Positive
Benzinga
2 months ago
Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside
On Monday, HC Wainwright initiated coverage on Septerna, Inc. SEPN, citing a next-generation drug design platform aimed at hitherto-undruggable targets.
Neutral
GlobeNewsWire
2 months ago
Septerna to Present at Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D.
Negative
MarketBeat
3 months ago
Analysts Think These Stocks Could More Than Double in Value
Persistent volatility has plagued the S&P 500 for much of 2025, prompting widespread caution among many investors amid the uncertainties of trade battles, tariffs, domestic policy, and more. Investors might remember that many of the biggest rallies take place during these volatile periods, and there may be potential to win big gains for those with at least a moderate tolerance for risk.
Positive
Zacks Investment Research
3 months ago
Does Septerna, Inc. (SEPN) Have the Potential to Rally 151.27% as Wall Street Analysts Expect?
The mean of analysts' price targets for Septerna, Inc. (SEPN) points to a 151.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Positive
Seeking Alpha
3 months ago
Septerna: Novo's Investment In Incretin Program Intrigues - One For The Watchlist
Septerna's partnership with Novo Nordisk is a strong endorsement, but the $195m upfront is modest (by Big Pharma standards) and milestone payments are not guaranteed. The company's innovative GPCR platform and deep pipeline are promising, yet early clinical setbacks and fierce competition raise execution risks. Septerna's cash position is solid for now, but future clinical expenses may require additional funding, potentially diluting current shareholders.
Positive
Seeking Alpha
3 months ago
Septerna: Deal With Novo Nordisk Is A Game Changer While It Still Trades Well Below Net Cash
Septerna's partnership with Novo Nordisk validates its GPCR drug discovery platform and injects $195 million in upfront cash, with potential for more than $2 billion in milestone payments. The stock trades below net cash even after the Novo deal, offering investors a rare opportunity to buy the pipeline and partnership essentially for free. NVO will cover R&D costs for four programs, extending SEPN's cash runway and reducing burn rate, while de-risking early-stage development.
Neutral
GlobeNewsWire
3 months ago
Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results
Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments
Positive
Zacks Investment Research
3 months ago
ETFs to Capitalize on the Novo Nordisk-Septerna Deal
Novo Nordisk announces a $2.2 billion deal with Septerna to tap the growing obesity treatment market.
Charts implemented using Lightweight Charts™